- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00996203
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.
28 lutego 2018 zaktualizowane przez: Hoffmann-La Roche
Local Open-label Multicenter Study to Evaluate the Quality of Life in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to DMARDs When Adding Tocilizumab (TCZ)
This open-label single arm study will evaluate the efficacy and safety of tocilizumab added to traditional disease-modifying antirheumatic drugs (DMARDs) in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDs.
Patients will receive tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 24 weeks, in addition to their current non-biologic DMARDs at stable doses.
Anticipated time on study treatment is 24 weeks, and the target sample size is 200.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
201
Faza
- Faza 4
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Chelyabinsk, Federacja Rosyjska, 454076
- Chelyabinsk Regional Clinical Hospital; Rheumatology
-
Cherkess, Federacja Rosyjska, 369000
- Republican clinical hospital of Karachai-Cherkess; Rheumatologic Department
-
Ekaterinburg, Federacja Rosyjska, 620102
- Municipal Autonomous Institution of Healthcare "City Clinical Hospital #40"
-
Ekaterinburg, Federacja Rosyjska, 620102
- Sverdlovsk Regional Clinical Hospital # 1; Rheumatology Dept
-
Irkutsk, Federacja Rosyjska, 664047
- Irkutsk Regional Consulting and Diagnostic Clinical Center; Regional Center of Reumatolodic Deasise
-
Izhevsk, Federacja Rosyjska, 426009
- Republican Clinicodiagnostic Center
-
Kaliningrad, Federacja Rosyjska, 236016
- Kaliningrad Regional Clinical Hospital; Rheumatologic Department
-
Kemerovo, Federacja Rosyjska, 650099
- War Veterans Regional Clinical Hospital;Therapy Department
-
Kirov, Federacja Rosyjska, 610028
- Kirov Regional Clinical Hospital; Reumatology Department
-
Krasnodar, Federacja Rosyjska, 350086
- GUZ Regional clinical hospital # 1
-
Kursk, Federacja Rosyjska, 305007
- GMU Kursk regional clinical hospital
-
Moscow, Federacja Rosyjska, 123060
- Head Clinical Hospital of Internal Affair Ministry of Russia
-
Moscow, Federacja Rosyjska, 129110
- Vladimirskiy Regional Scientific Research Inst.
-
Moscow, Federacja Rosyjska, 115522
- FSBI "Scientific Research Institute of Rheumatology" of russian Academy of Medical Sciences
-
Moscow, Federacja Rosyjska, 115682
- FSBI "FSCC of particularized sorts of medical care and medical technologies of FMBA"
-
Moscow, Federacja Rosyjska, 121359
- FGU Central Clinical Hospital with Polyclinic Administration President RF
-
Nizhny Novgorod, Federacja Rosyjska, 603126
- SIH Nizhny Novgorod Regional Clinical Hospital n.a. Semashko
-
Petrozavodsk, Federacja Rosyjska, 185019
- Republican Hospital named after V.A. Baranov
-
Rostov-na-Donu, Federacja Rosyjska, 344022
- Rostov State Medical University; Cardiorheumatology Department
-
Smolensk, Federacja Rosyjska, 214001
- Clinical hospital #1
-
Surgut, Federacja Rosyjska, 628408
- Surgut Region Clinical Hospital
-
Tjumen, Federacja Rosyjska, 625023
- Glpu Tjumen Regional Clinical Hospital #1
-
UFA, Federacja Rosyjska, 450005
- Republican clinical hospital named after G.G. Kuvatov
-
Ulyanovsk, Federacja Rosyjska, 432063
- State Institution of Healthcare Ulyanovsk Regional Clinical Hospital
-
Veliky Novgorod, Federacja Rosyjska, 173008
- GUZ "Novgorod Regional Clinical Hospital"; Cardioreumatological
-
Voronezh, Federacja Rosyjska, 394066
- Voronezh Regional Clinical Hospital #1
-
Voronezh, Federacja Rosyjska, 394066
- Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1"
-
Yaroslavl, Federacja Rosyjska, 150062
- SHI Yaroslavl Regional Clinical Hospital
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- adult patients, >/= 18 years of age
- moderate to severe active rheumatoid arthritis of >/=6 months duration
- inadequate clinical response to current non-biologic DMARDs
- current DMARDs must be at stable dose for 8 weeks prior to study entry
- oral corticosteroids (</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for >/=4 weeks prior to screening
Exclusion Criteria:
- rheumatic autoimmune disease other than RA
- history of or current inflammatory joint disease other than RA
- previous treatment with any biologic DMARD
- functional class IV as defined by the ACR classification
- intra-articular or parenteral corticosteroids within 6 weeks prior to screening
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: 1
|
8 mg/kg iv every 4 weeks for 24 weeks
stable doses at investigator's prescription
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Health Assessment Questionnaire (HAQ) Score
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3. Withdrawal Visit is the final visit prior to the withdrawal of the subject from the study.
|
Weeks 0, 4, 8, 12, 16, 20, and 24 and Withdrawal Visit
|
|
Percentage of Participants With an HAQ Score Decrease of 20 Percent (%), 50%, and 70% During Tocilizumab Treatment
Ramy czasowe: Weeks 4, 8, 12, 16, 20, and 24
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
Change in HAQ Score at Week 24
Ramy czasowe: Baseline and Week 24
|
HAQ includes 20 questions concerning participant's activities of daily life, grouped in 8 scales of 2 to 3 questions for each activity.
To respond to each question, a four-level response (score of 0 to 3 points), with higher scores showing larger functional limitations, was chosen.
Scoring was as follows with respect to performance of participant's everyday activities: 0=without difficulties; 1=with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all.
Minimum score was 0, maximum score was 3.
|
Baseline and Week 24
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pain Score as Assessed by Visual Analogue Scale (VAS)
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant's global assessment of pain was assessed using a 100-millimeter (mm) horizontal VAS (0 to 100 mm) with 0=pain absent and 100=intolerable pain.
Participants responded by placing a mark on the line to indicate their current level of pain.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
European Quality of Life - 5 Dimensions (EQ-5D) Score
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression.
Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances.
Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in EQ-5D Score at Week 24 From Baseline
Ramy czasowe: Baseline and Week 24
|
EQ-5D questionnaire assess 5 domains of quality of life including mobility, self-care, habitual daily activities, pain, discomfort, and anxiety/depression.
Each of five domains was assessed by 3 levels depending on severity of a problem and scored using the following: 1=no disturbances, 2=moderate disturbances, 3=severe disturbances.
Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Minimum clinically significant change in EQ-5D corresponds to the parameter differences before and after treatment = 0.10.
Graduations of assessment of the therapy efficacy by EQ-5D are: Difference (Δ) EQ-5D less than (<)0.10 points: none; 0.10 less than or equal to (≤)Δ EQ-5D ≤0.24: minimal effect; 0.24≤ Δ EQ-5D <0.31: satisfactory effect; Δ EQ-5D greater than or equal to (≥)0.31 points: pronounced effect.
|
Baseline and Week 24
|
|
General Health Score as Assessed by EQ-5D VAS
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants Achieving a Positive Response on Health Quality Assessment of EQ-5D
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
Positive response was defined as an increase of EQ-5D score by 0.1 or more i.e. it is a clinically significant increase.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in General Health Assessed by VAS
Ramy czasowe: Baseline and Week 24
|
Participant-reported general health quality was assessed using an EQ-5D 100-mm horizontal VAS (0 to 100 mm) with 0=worst health state and 100=the best health state.
The participants were asked to mark the line that corresponded to assessment of general health quality.
|
Baseline and Week 24
|
|
Disease Activity Score Based on 28-Joint Count (DAS28)
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Change in DAS28 Score From Baseline to Week 24
Ramy czasowe: Baseline and Week 24
|
Baseline and Week 24
|
|
|
Percentage of Patients With Varied Disease Activity Assessed Using DAS28 During Tocilizumab Treatment
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
DAS28 calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR mm/hour, and global health assessment (participant rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity.
Disease activity: 0=remission (DAS28 less than [<] 2.6), I=low (DAS28 less than or equal to [≤]2.6 to <3.2), II=moderate (DAS28=3.2
to 5.1), III=high (DAS28 greater than [>]5.1).
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20), 50% (ACR50), and 70% (ACR70) Response
Ramy czasowe: Weeks 0, 4, 8, 12, 16, 20, and 24
|
ACR20/50/70 response: ≥20%, ≥50%, or ≥70% improvement, respectively, in swollen/tender joint count (66 joints assessed for swelling and 68 joints assessed for tenderness) and in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and acute phase response: C-reactive protein (CRP) or ESR.
|
Weeks 0, 4, 8, 12, 16, 20, and 24
|
|
Percentage of Participants With European League Against Rheumatism (EULAR) Response Based on DAS28
Ramy czasowe: Weeks 4, 8, 12, 16, 20, and 24
|
The DAS28-based EULAR response criteria were used to measure individual response as no effect, good effect, and moderate effect, depending on the extent of change from baseline and the level of disease activity reached.
Good effect: change from baseline >1.2 with DAS28 score ≤3.2; moderate effect: change from baseline >1.2 with DAS28 score 3.2 to 5.1 or change from baseline >0.6 to <1.2 with DAS28 score <3.2; no effect: change from baseline ≤0.6 or change from baseline >0.6 and ≤1.2 with DAS28 score >5.1.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
C-Reactive Protein
Ramy czasowe: Weeks 4, 8, 12, 16, 20, and 24
|
CRP (milligrams/Liter) is a mediator of inflammation, acute phase protein.
|
Weeks 4, 8, 12, 16, 20, and 24
|
|
Erythrocyte Sedimentation Rate
Ramy czasowe: Weeks 4, 8, 12, 16, 20, and 24
|
ESR (mm/hr) is used to determine the acute phase response.
|
Weeks 4, 8, 12, 16, 20, and 24
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
31 października 2009
Zakończenie podstawowe (Rzeczywisty)
14 lutego 2011
Ukończenie studiów (Rzeczywisty)
14 lutego 2011
Daty rejestracji na studia
Pierwszy przesłany
15 października 2009
Pierwszy przesłany, który spełnia kryteria kontroli jakości
15 października 2009
Pierwszy wysłany (Oszacować)
16 października 2009
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
29 marca 2018
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
28 lutego 2018
Ostatnia weryfikacja
1 lutego 2018
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- ML22665
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .